Last reviewed · How we verify

Tussionex Pennkinetic (chlorphenamine)

Bayer · FDA-approved active Quality 36/100

Tussionex Pennkinetic, also known as chlorphenamine, is a small molecule histamine-1 receptor antagonist developed by BAYER HEALTHCARE LLC. It was first approved by the FDA in 1950 for various allergic conditions, including allergic conjunctivitis, rhinitis, and skin itching. As a histamine-1 receptor antagonist, Tussionex Pennkinetic works by blocking the action of histamine at its receptor site, thereby reducing symptoms of allergic reactions. The commercial status of Tussionex Pennkinetic is owned by BAYER HEALTHCARE LLC, and its key safety considerations include its potential for drowsiness and interactions with other medications. Overall, Tussionex Pennkinetic is a well-established medication for the treatment of allergic conditions.

At a glance

Generic namechlorphenamine
SponsorBayer
Drug classHistamine-1 Receptor Antagonist
TargetHistamine H1 receptor
Therapeutic areaImmunology
PhaseFDA-approved
First approval1950

Approved indications

Common side effects

Serious adverse events

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: